Genomic Health, Inc. (NASDAQ:GHDX) was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

Several other analysts have also commented on the stock. Zacks Investment Research lowered shares of Genomic Health from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st. Jefferies Group LLC reissued a “hold” rating and set a $33.00 price target on shares of Genomic Health in a research report on Monday, June 12th. Raymond James Financial, Inc. reissued a “market perform” rating on shares of Genomic Health in a research report on Wednesday, May 3rd. They noted that the move was a valuation call. Piper Jaffray Companies reissued a “hold” rating and set a $31.00 price target on shares of Genomic Health in a research report on Thursday, August 3rd. Finally, Canaccord Genuity decreased their price target on shares of Genomic Health from $36.00 to $35.00 and set a “buy” rating for the company in a research report on Tuesday, August 15th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and one has assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $32.00.

Genomic Health (NASDAQ GHDX) traded down 0.69% during midday trading on Friday, reaching $30.25. 53,888 shares of the company’s stock traded hands. The company’s 50-day moving average price is $31.54 and its 200-day moving average price is $31.34. The stock’s market cap is $1.05 billion. Genomic Health has a 52-week low of $25.77 and a 52-week high of $33.97.

Genomic Health (NASDAQ:GHDX) last released its quarterly earnings data on Tuesday, August 1st. The medical research company reported ($0.08) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.06) by $0.02. Genomic Health had a negative return on equity of 4.33% and a negative net margin of 1.50%. The business had revenue of $85.50 million during the quarter, compared to analysts’ expectations of $86.08 million. During the same period last year, the company earned ($0.18) earnings per share. The firm’s revenue was up 4.3% compared to the same quarter last year. On average, equities analysts predict that Genomic Health will post ($0.01) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Genomic Health, Inc. (GHDX) Upgraded to Hold by BidaskClub” was originally published by American Banking News and is the property of of American Banking News. If you are accessing this report on another domain, it was illegally stolen and republished in violation of international copyright legislation. The correct version of this report can be read at https://www.americanbankingnews.com/2017/08/26/genomic-health-inc-ghdx-upgraded-to-hold-by-bidaskclub.html.

In other news, CEO Kimberly J. Popovits sold 1,468 shares of the company’s stock in a transaction dated Wednesday, July 5th. The shares were sold at an average price of $32.67, for a total transaction of $47,959.56. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Steven Shak sold 5,000 shares of the company’s stock in a transaction dated Friday, June 23rd. The shares were sold at an average price of $33.27, for a total transaction of $166,350.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 42,642 shares of company stock valued at $1,356,731. Insiders own 46.20% of the company’s stock.

Several institutional investors have recently bought and sold shares of GHDX. American International Group Inc. increased its position in Genomic Health by 7.1% in the first quarter. American International Group Inc. now owns 11,505 shares of the medical research company’s stock valued at $362,000 after buying an additional 765 shares during the period. Los Angeles Capital Management & Equity Research Inc. bought a new position in Genomic Health during the first quarter valued at about $218,000. Nordea Investment Management AB increased its position in Genomic Health by 28.7% in the first quarter. Nordea Investment Management AB now owns 53,607 shares of the medical research company’s stock valued at $1,688,000 after buying an additional 11,970 shares during the period. Envestnet Asset Management Inc. increased its position in Genomic Health by 13.6% in the first quarter. Envestnet Asset Management Inc. now owns 8,282 shares of the medical research company’s stock valued at $259,000 after buying an additional 993 shares during the period. Finally, Airain ltd bought a new position in Genomic Health during the first quarter valued at about $285,000. Hedge funds and other institutional investors own 88.54% of the company’s stock.

Genomic Health Company Profile

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Analyst Recommendations for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.